Trials / Completed
CompletedNCT03246828
Glucagon in MODY (Maturity Onset Diabetes of the Young)
Investigating Glucagon Secretion in HNF1-alpha and HNF4-alpha MODY
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- University of Oxford · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to determine whether fasting and post-prandial glucagon secretion is suppressed by gliclazide in patients with HNF1-/4-alpha MODY. Participants will undergo an oral glucose tolerance test (OGTT) before and after omitting their gliclazide medication for 3 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Omission of gliclazide | Participants will stop taking gliclazide for 3 days. Data from the OGTT will be compared with that prior to stopping the medication. |
Timeline
- Start date
- 2017-07-03
- Primary completion
- 2022-07-29
- Completion
- 2022-08-01
- First posted
- 2017-08-11
- Last updated
- 2022-08-17
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03246828. Inclusion in this directory is not an endorsement.